Darzalex

10 Rock-Solid Reasons Johnson & Johnson's Near-Term Future Looks Bright
10 Rock-Solid Reasons Johnson & Johnson's Near-Term Future Looks Bright
Motley Fool
JNJ
Remicade
Stelara
drug pricing
Imbruvica
Xarelto
Darzalex
devices
consumer health
Flag link:
Genmab gains on promising early success for daratumumab PhIII in multiple myeloma, but questions linger
Genmab gains on promising early success for daratumumab PhIII in multiple myeloma, but questions linger
Endpoints
Genmab
daratumumab
Darzalex
Multiple Myeloma
clinical trials
Flag link:
Johnson & Johnson nabs another combo approval for myeloma star Darzalex
Johnson & Johnson nabs another combo approval for myeloma star Darzalex
Fierce Pharma
JNJ
Multiple Myeloma
Darzalex
Flag link:
3 Big Pharma Companies With the Best Pipelines
3 Big Pharma Companies With the Best Pipelines
Motley Fool
JNJ
Actelion
Darzalex
Novartis
Cosentyx
Jakavi
Lucentis
Tasigna
Roche
Venclexta
Tecentriq
emicizumab
Flag link:
Looking for Darzalex sales expansion, J&J, Genmab hit a wall in lymphoma
Looking for Darzalex sales expansion, J&J, Genmab hit a wall in lymphoma
Fierce Pharma
Darzalex
JNJ
Genmab
non-Hodgkin's lymphoma
Flag link:
J&J pulls the plug on PhII study for NHL after Darzalex falls short
J&J pulls the plug on PhII study for NHL after Darzalex falls short
Endpoints
JNJ
clinical trials
Darzalex
Flag link:
4 Reasons Johnson & Johnson Surged 8% in February
4 Reasons Johnson & Johnson Surged 8% in February
Motley Fool
JNJ
Darzalex
Actelion
Donald Trump
Flag link:
Johnson & Johnson May Already Have Its Remicade Replacement Well in Hand
Johnson & Johnson May Already Have Its Remicade Replacement Well in Hand
Motley Fool
JNJ
Remicade
Darzalex
Genmab
Multiple Myeloma
Flag link:
Is This Johnson & Johnson's Next Billion-Dollar Blockbuster?
Is This Johnson & Johnson's Next Billion-Dollar Blockbuster?
Motley Fool
JNJ
Darzalex
Multiple Myeloma
Flag link:
3 Biggest Risks for Celgene Corporation
3 Biggest Risks for Celgene Corporation
Motley Fool
Celgene
Darzalex
Multiple Myeloma
Allergan
generics
Abraxane
Revlimid
Flag link:
You'll Never Guess Who Owns the Most Spectacular New Cancer Drug
You'll Never Guess Who Owns the Most Spectacular New Cancer Drug
Motley Fool
JNJ
Darzalex
Multiple Myeloma
Flag link:
Here Are Johnson & Johnson's Next 10 Potential Blockbuster Drugs
Here Are Johnson & Johnson's Next 10 Potential Blockbuster Drugs
Motley Fool
JNJ
Darzalex
sirukumab
guselkumab
imetelstat
Flag link:
This $6.7 Billion Drug Just Keeps Growing
This $6.7 Billion Drug Just Keeps Growing
Motley Fool
JNJ
Darzalex
Celgene
Revlimid
Flag link:
J&J myeloma drug, in combo regimen, delays worsening of the disease
J&J myeloma drug, in combo regimen, delays worsening of the disease
Yahoo/Reuters
JNJ
Multiple Myeloma
Darzalex
Takeda
Velcade
ASCO 2016
Flag link:
Amgen's Kyprolis stands its ground against new J&J, BMS rivals
Amgen's Kyprolis stands its ground against new J&J, BMS rivals
Fierce Pharma
Amgen
Kyprolis
JNJ
Bristol-Myers Squibb
Multiple Myeloma
Darzalex
Empliciti
AbbVie
Takeda
Ninlaro
Flag link:
J&J joins up with Genentech for a pair of atezo/Darzalex combo cancer studies
J&J joins up with Genentech for a pair of atezo/Darzalex combo cancer studies
Fierce Biotech
JNJ
Genentech
Darzalex
atezolizumab
Flag link:
3 Potential Blockbusters Moving the Needle for Big Pharma in 2016
3 Potential Blockbusters Moving the Needle for Big Pharma in 2016
Motley Fool
Big Pharma
JNJ
Novartis
Bristol-Myers Squibb
Darzalex
Entresto
Opdivo
Flag link:
Johnson & Johnson's Latest FDA Approval Could Spell Problems for Amgen
Johnson & Johnson's Latest FDA Approval Could Spell Problems for Amgen
Motley Fool
JNJ
FDA
Amgen
Darzalex
daratumumab
Multiple Myeloma
Flag link:
J&J nabs an early OK for 'breakthrough' multiple myeloma blockbuster contender Darzalex
J&J nabs an early OK for 'breakthrough' multiple myeloma blockbuster contender Darzalex
Fierce Biotech
JNJ
Multiple Myeloma
daratumumab
FDA
Darzalex
Genmab
Flag link: